New antibody drug aims to boost platelets in Hard-to-Treat ITP
NCT ID NCT07043946
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called budoprutug (TNT119) in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive two IV doses and are monitored for safety, how the drug moves through the body, and any signs it helps raise platelet counts. The goal is to see if this approach is safe and worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
budoprutug (TNT119), a monoclonal antibody given by IV infusion
What this could lead to
If it works, this could point toward a new treatment option for people with immune thrombocytopenia (ITP) who haven't responded to other therapies.
What could go wrong
This is an early, small trial (24 people) focused mainly on safety. It may not show clear benefit, and side effects are possible. Even if promising, more studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Climb Bio Investigative Site #300201
RECRUITINGThessaloniki, 57010, Greece
-
Climb Bio Investigative Site #300202
RECRUITINGIoannina, 45500, Greece
-
Climb Bio Investigative Site #300203
RECRUITINGChaïdári, Attica, 12462, Greece
-
Climb Bio Investigative Site #300204
RECRUITINGAthens, Attica, 11527, Greece
-
Climb Bio Investigative Site #340202
RECRUITINGSan Pedro, Spain
-
Climb Bio Investigative Site #340203
RECRUITINGValencia, 46010, Spain
-
Climb Bio Investigative Site #340204
RECRUITINGMadrid, 28041, Spain
-
Climb Bio Investigative Site #340206
NOT_YET_RECRUITINGBurgos, 9006, Spain
-
Climb Bio Investigative Site #359201
RECRUITINGSofia, 1797, Bulgaria
-
Climb Bio Investigative Site #359202
RECRUITINGPlovdiv, 4002, Bulgaria
-
Climb Bio Investigative Site #359203
RECRUITINGPlovdiv, 4003, Bulgaria
-
Climb Bio Investigative Site #380208
NOT_YET_RECRUITINGCherkasy, Ukraine
-
Climb Bio Investigative Site #381201
RECRUITINGBelgrade, Serbia
-
Climb Bio Investigative Site #381202
RECRUITINGBelgrade, Serbia
-
Climb Bio Investigative Site #381203
RECRUITINGNovi Sad, Serbia
-
Climb Investigative Site #2380203
RECRUITINGKyiv, Ukraine
-
Climb Investigative Site #380201
RECRUITINGLviv, Ukraine
-
Climb Investigative Site #380202
RECRUITINGKyiv, Ukraine
-
Climb Investigative Site #380204
RECRUITINGIvano-Frankivsk, Ukraine
-
Climb Investigative Site #380206
RECRUITINGKyiv, Ukraine